NCT03042702View on ClinicalTrials.gov

A Phase 2 Study of Kevetrin in Subjects With Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

November 10, 2017

Study Completion Date

November 10, 2017

Conditions
Ovarian Cancer
Interventions
DRUG

Kevetrin

Kevetrin dose to associated cohort

DRUG

Kevetrin

Kevetrin dose to associated cohort

Trial Locations (2)

75230

Cancer Research, Dallas

03766

Cancer Research, Lebanon

Sponsors
All Listed Sponsors
lead

Innovation Pharmaceuticals, Inc.

INDUSTRY